Upstream Bio NasdaqGS:UPB Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases focusing on severe respiratory disorders. Its product candidate includes verekitug, which is in Phase 2 clinical development for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps, as well as in Phase I clinical trial for treating chronic obstructive pulmonary disease. The company was incorporated in 2021 and is headquartered in Waltham, Massachusetts.

Location: 890 Winter Street, Waltham, MA, 02451, United States | Website: https://upstreambio.com | Industry: Biotechnology | Sector: Healthcare